Zarogoulidis Paul, Steiropoulos Paschalis, Perantoni Eleni, Archontogeorgis Konstantinos, Eleftheriadou Ellada, Porpodis Konstantinos, Charpidou Anna G, Angelopoulou Christina, Nena Evangelia, Zarogoulidis Konstantinos, Tsara Venetia
Department of Pneumonology, Medical School, Aristotle University of Thessaloniki, General Hospital "G. Papanikolaou", Thessaloniki, Greece Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece Sleep Unit, 2nd Pulmonary Department, General Hospital "G. Papanikolaou", Thessaloniki, Greece Neurology Department (NHS), University General Hospital of Alexandroupolis, Alexandroupolis, Greece.
Thorac Cancer. 2013 May;4(2):138-142. doi: 10.1111/j.1759-7714.2012.00156.x.
Sleep disturbances, such as difficulty in falling asleep, maintaining sleep, poor sleep efficiency, early awakening, and excessive daytime sleepiness, are common in patients with cancer. The aim of this study was to evaluate sleep characteristics in newly diagnosed lung cancer patients before and after three months of chemotherapy treatment.
Forty-nine patients with lung cancer, without brain metastasis, were included. Anthropometric and disease characteristics were collected. Upon diagnosis and after three months, a polysomnographic examination was conducted and the patients completed the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Fatigue Severity Scale (FSS) and the Medical Research Council (MRC) dyspnoea scale.
Before chemotherapy, the mean PSQI score was 7.1 ± 4, the FSS score was 3.92 ± 2, and the ESS score was 6.8 ± 4. The MRC score was low at 1.6 ± 1.1. A significant correlation between FSS and global PSQI was revealed (r = 0.424, P < 0.01), as well as with several of the PSQI components. After chemotherapy, no statistically significant change was observed in the PSQI (mean: 6.6 ± 4.5, t-score: 0.784, P = 0.438), or the FSS score (4.4 ± 2.2, t-score: -1.375, P = 0.177). Sleep efficiency was significantly reduced (P = 0.008), without any change in the distribution of sleep stages.
The perception of sleep quality is poor among newly diagnosed lung cancer patients and is correlated with fatigue. After chemotherapy, self-reported sleep impairment is present and sleep efficiency is reduced, without significant change in sleep architecture.
睡眠障碍，如入睡困难、维持睡眠困难、睡眠效率低下、早醒和日间过度嗜睡，在癌症患者中很常见。本研究的目的是评估新诊断肺癌患者在化疗治疗三个月前后的睡眠特征。
纳入49例无脑转移的肺癌患者。收集人体测量和疾病特征。在诊断时和三个月后，进行多导睡眠图检查，患者完成爱泼沃斯思睡量表（ESS）、匹兹堡睡眠质量指数（PSQI）、疲劳严重程度量表（FSS）和医学研究委员会（MRC）呼吸困难量表。
化疗前，PSQI平均评分为7.1±4，FSS评分为3.92±2，ESS评分为6.8±4。MRC评分为1.6±1.1，较低。FSS与整体PSQI之间存在显著相关性（r = 0.424，P < 0.01），与PSQI的几个组成部分也存在显著相关性。化疗后，PSQI（平均值：6.6±4.5，t值：0.784，P = 0.438）或FSS评分（4.4±2.2，t值：-1.375，P = 0.177）无统计学显著变化。睡眠效率显著降低（P = 0.008），睡眠阶段分布无变化。
新诊断肺癌患者的睡眠质量感知较差，且与疲劳相关。化疗后，存在自我报告的睡眠障碍，睡眠效率降低，睡眠结构无显著变化。
